Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Ultrasound J ; 13(1): 24, 2021 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-33877462

RESUMO

BACKGROUND: Ultrasound was first introduced in clinical dermatology in 1979. Since that time, ultrasound technology has continued to develop along with its popularity and utility. Today, high-frequency ultrasound (HFUS), or ultrasound using a frequency of at least 10 megahertz (MHz), allows for high-resolution imaging of the skin from the stratum corneum to the deep fascia. This non-invasive and easy-to-interpret tool allows physicians to assess skin findings in real-time, enabling enhanced diagnostic, management, and surgical capabilities. In this review, we discuss how HFUS fits into the landscape of skin imaging. We provide a brief history of its introduction to dermatology, explain key principles of ultrasonography, and review its use in characterizing normal skin, common neoplasms of the skin, dermatologic diseases and cosmetic dermatology. CONCLUSION: As frequency advancements in ultrasonography continue, the broad applications of this imaging modality will continue to grow. HFUS is a fast, safe and readily available tool that can aid in diagnosing, monitoring and treating dermatologic conditions by providing more objective assessment measures.

2.
Elife ; 92020 06 19.
Artigo em Inglês | MEDLINE | ID: mdl-32558644

RESUMO

Previously, we showed that 3% (31/1032)of asymptomatic healthcare workers (HCWs) from a large teaching hospital in Cambridge, UK, tested positive for SARS-CoV-2 in April 2020. About 15% (26/169) HCWs with symptoms of coronavirus disease 2019 (COVID-19) also tested positive for SARS-CoV-2 (Rivett et al., 2020). Here, we show that the proportion of both asymptomatic and symptomatic HCWs testing positive for SARS-CoV-2 rapidly declined to near-zero between 25th April and 24th May 2020, corresponding to a decline in patient admissions with COVID-19 during the ongoing UK 'lockdown'. These data demonstrate how infection prevention and control measures including staff testing may help prevent hospitals from becoming independent 'hubs' of SARS-CoV-2 transmission, and illustrate how, with appropriate precautions, organizations in other sectors may be able to resume on-site work safely.


Assuntos
Técnicas de Laboratório Clínico/estatística & dados numéricos , Infecções por Coronavirus/transmissão , Pessoal de Saúde , Programas de Rastreamento/estatística & dados numéricos , Doenças Profissionais/prevenção & controle , Pandemias , Pneumonia Viral/transmissão , Adulto , Doenças Assintomáticas , Betacoronavirus/genética , Betacoronavirus/isolamento & purificação , COVID-19 , Teste para COVID-19 , Infecções Comunitárias Adquiridas/transmissão , Busca de Comunicante , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Transmissão de Doença Infecciosa/prevenção & controle , Inglaterra/epidemiologia , Características da Família , Feminino , Unidades Hospitalares , Hospitais de Ensino/organização & administração , Hospitais de Ensino/estatística & dados numéricos , Hospitais Universitários/organização & administração , Hospitais Universitários/estatística & dados numéricos , Humanos , Controle de Infecções , Transmissão de Doença Infecciosa do Paciente para o Profissional/estatística & dados numéricos , Masculino , Programas de Rastreamento/organização & administração , Pessoa de Meia-Idade , Nasofaringe/virologia , Doenças Profissionais/epidemiologia , Pandemias/prevenção & controle , Admissão do Paciente/estatística & dados numéricos , Pneumonia Viral/diagnóstico , Pneumonia Viral/epidemiologia , Pneumonia Viral/prevenção & controle , Prevalência , Avaliação de Programas e Projetos de Saúde , Reação em Cadeia da Polimerase em Tempo Real , SARS-CoV-2 , Avaliação de Sintomas
4.
Am J Dermatopathol ; 39(3): 217-224, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28195843

RESUMO

Lipophagic panniculitis of childhood is a rare condition notable clinically for an inflammatory panniculitis followed by the development of permanent lipoatrophy. In this regard, the term lipoatrophic panniculitis has been used synonymously with lipophagic panniculitis. Additional designations include lipophagic lipoatrophic panniculitis and annular lipoatrophic panniculitis of the ankles. Although lipophagic panniculitis has been associated with a number of autoimmune phenomena, a paucity of reports and limited pathological analyses to date renders this disease an elusive one whose pathogenesis is not yet established. We describe the clinical, histopathologic, and immunohistochemical findings in a case of lipophagic panniculitis of childhood in a 7-year-old boy and present it in the context of a comprehensive review of the literature. Furthermore, we offer a hypothesis regarding the pathogenetic basis of lipophagic panniculitis of childhood, suggesting cellular immunity targeting the adipocyte at the crux of its pathogenesis.


Assuntos
Lipodistrofia/diagnóstico , Paniculite/diagnóstico , Pele/patologia , Gordura Subcutânea/patologia , Anti-Inflamatórios/uso terapêutico , Atrofia , Biomarcadores/análise , Biópsia , Criança , Quimioterapia Combinada , Humanos , Imuno-Histoquímica , Imunossupressores/uso terapêutico , Lipodistrofia/tratamento farmacológico , Lipodistrofia/imunologia , Lipodistrofia/patologia , Masculino , Paniculite/tratamento farmacológico , Paniculite/imunologia , Paniculite/patologia , Valor Preditivo dos Testes , Pele/efeitos dos fármacos , Pele/imunologia , Gordura Subcutânea/efeitos dos fármacos , Gordura Subcutânea/imunologia , Resultado do Tratamento
5.
Clin Vaccine Immunol ; 18(9): 1510-8, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21734063

RESUMO

The human papillomavirus type 16/18 (HPV-16/18) AS04-adjuvanted cervical cancer vaccine is licensed for females aged 10 years and above and is therefore likely to be coadministered with other licensed vaccines, such as hepatitis B. In this randomized, open-label study, we compared the immunogenicity of the hepatitis B vaccine administered alone (HepB group) or with the HPV-16/18 AS04-adjuvanted vaccine (HepB+HPV group) in healthy women aged 20 to 25 years (clinical trial NCT00637195). The hepatitis B vaccine was given at 0, 1, 2, and 12 months (an accelerated schedule which may be required by women at high risk), and the HPV-16/18 vaccine was given at 0, 1, and 6 months. One month after the third dose of hepatitis B vaccine, in the according-to-protocol cohort (n = 72 HepB+HPV; n = 76 HepB), hepatitis B seroprotection rates (titer of ≥10 mIU/ml) were 96.4% (95% confidence interval [CI], 87.5 to 99.6) and 96.9% (CI, 89.2 to 99.6) in the HepB+HPV and HepB groups, respectively, in women initially seronegative for anti-hepatitis B surface antigen (HBs) and anti-hepatitis B core antigen (HBc). Corresponding geometric mean titers of anti-HBs antibodies were 60.2 mIU/ml (CI, 40.0 to 90.5) and 71.3 mIU/ml (CI, 53.9 to 94.3). Anti-HBs antibody titers rose substantially after the fourth dose of hepatitis B vaccine. All women initially seronegative for anti-HPV-16 and anti-HPV-18 antibodies seroconverted after the second HPV-16/18 vaccine dose and remained seropositive up to 1 month after the third dose. Both vaccines were generally well tolerated, with no difference in reactogenicity between groups. In conclusion, coadministration of the HPV-16/18 AS04-adjuvanted vaccine did not affect the immunogenicity or safety of the hepatitis B vaccine administered in an accelerated schedule in young women.


Assuntos
Vacinas Anticâncer/administração & dosagem , Vacinas contra Hepatite B , Hepatite B/prevenção & controle , Papillomavirus Humano 16/imunologia , Papillomavirus Humano 18/imunologia , Neoplasias do Colo do Útero/prevenção & controle , Adjuvantes Imunológicos/administração & dosagem , Adulto , Hidróxido de Alumínio/administração & dosagem , Hidróxido de Alumínio/imunologia , Anticorpos Antivirais/sangue , Vacinas Anticâncer/imunologia , Feminino , Hepatite B/imunologia , Hepatite B/virologia , Anticorpos Anti-Hepatite B/sangue , Vacinas contra Hepatite B/administração & dosagem , Vacinas contra Hepatite B/efeitos adversos , Vacinas contra Hepatite B/imunologia , Vírus da Hepatite B/imunologia , Humanos , Lipídeo A/administração & dosagem , Lipídeo A/análogos & derivados , Lipídeo A/imunologia , Infecções por Papillomavirus/imunologia , Infecções por Papillomavirus/prevenção & controle , Infecções por Papillomavirus/virologia , Vacinas contra Papillomavirus/administração & dosagem , Vacinas contra Papillomavirus/imunologia , Resultado do Tratamento , Neoplasias do Colo do Útero/imunologia , Neoplasias do Colo do Útero/virologia , Adulto Jovem
6.
Int J Pediatr Otorhinolaryngol ; 70(1): 155-8, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16026861

RESUMO

In most hospitals, making a microscopic examination to tonsil and adenoid specimens from pediatric patients who present recurrent infections has become a standard practice. However, studies have shown that systematic examination of tonsils and adenoids was not needed for individual aged 21 or less. In this context, we describe the third report of an unsuspected tonsillar sarcoidosis revealed by histologic examination. A 5-year-old white girl was referred to our department because of frequent nasal and pharyngeal infections. Both tonsillectomy and adenoïdectomy were performed. Histologic evaluation revealed noncaseous epithelioid granulomas morphologically compatible with a diagnosis of sarcoidosis. Our observation illustrates the benefit of histological analysis in every tonsillectomy and adenoïdectomy specimen.


Assuntos
Tonsila Palatina/patologia , Tonsila Palatina/cirurgia , Sarcoidose/diagnóstico , Tonsilite/cirurgia , Adenoidectomia , Pré-Escolar , Diagnóstico Diferencial , Feminino , Granuloma , Humanos , Recidiva , Tonsilectomia , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA